The project, headed by group leader and ICREA researcher Eduard Batlle, receives a 60,000-€ grant.
The study will test the effectiveness of immunotherapies to treat metastatic disease in advanced colorectal cancer.
Research will take place during the academic years 2017 and 2018.
It is a disease of the liver caused by excessive fat deposits in liver cells.
It is now the most prevalent chronic liver disease in industrialised countries and is a major public health concern because it leads to serious liver conditions.
IRB Barcelona organises a new year-long workshop in the life sciences within the series “Crazy About Science”, run by the Fundació Catalunya – La Pedrera.
“Crazy About Biomedicine” seeks to satisfy students’ interest in science and give them the chance to get a taste of what doing science in a top-class centre is like.
The international team achieved it by discovering the rules behind a type of protein structures that are essential for the interaction between proteins and small molecules
IRB Barcelona researcher, Enrique Marcos, is the first author of the study published today in Science
Researchers at IRB Barcelona identify a fundamental role of the JAK/STAT signalling pathway in the development and growth regulation of limbs in Drosophila.
Published in Nature Communications, the study paves the way to research into the function of this pathway in vertebrate development and its possible involvement in human congenital diseases.
The VI National 'Doctores Diz Pintado' Cancer Research Prize acknowledges his work and scientific career.
A bioinformatics analysis of pairing 64 drugs used to treat breast cancer allows researchers at IRB Barcelona to identify 10 previously untested combinations with potential to tackle resistance to breast cancer treatment.
In spite of the many drugs available to treat breast cancer, resistance continues to be a problem.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.
Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.
In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.
Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.
IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.